

Teva announces launch of generic version of EXJADE®

25 March 2019 | News

Deferasirox Tablets for Oral Suspension are indicated for the treatment of chronic iron overload due to blood transfusions



Teva Pharmaceutical has announced the launch of a generic version of EXJADE®1 (deferiasirox) Tablets for Oral Suspension, 125 mg, 250 mg and 500 mg, in the U.S.

Deferiasirox Tablets for Oral Suspension are an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients two years of age and older.

Brendan O'Grady, EVP and Head of North America Commercial said, "We're proud to offer an affordable generic treatment option with the launch of Deferiasirox Tablets for Oral Suspension in the U.S. We continue striving to enable access to medicines for people living with chronic, complex conditions."

EXJADE® had annual sales of \$134 million in the U.S., according to IQVIA data as of December 2018.

Deferiasirox Tablets for Oral Suspension are indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.